Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk

2020 . Weisel, Katja | Spencer, Andrew | Lentzsch, Suzanne | Avet-Loiseau, Hervé | Mark, Tomer M. | Spicka, Ivan | Masszi, Tamas | Lauri, Birgitta | Levin, Mark-David | Bosi, Alberto | Hungria, Vania | Cavo, Michele | Lee, Je-Jung | Nooka, Ajay | Quach, Hang | Munder, Markus | Lee, Cindy | Barreto, Wolney | Corradini, Paolo | Min, Chang-Ki | Chanan-Khan, Asher A. | Horvath, Noemi | Capra, Marcelo | Beksac, Meral | Ovilla, Roberto | Jo, Jae-Cheol | Shin, Ho-Jin | Sonneveld, Pieter | Casneuf, Tineke | DeAngelis, Nikki | Amin, Himal | Ukropec, Jon | Kobos, Rachel | Mateos, Maria-Victoria